Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross‐sectional study

Abstract excerpt

BACKGROUND AND AIMS: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are often comorbid and stigmatized. This can negatively affect quality of life (QOL). Other studies have primarily used the Chronic Liver Disease Questionnaire (CLDQ), which focuses on liver-related symptoms, to characterize QOL, but most MASLD patients have only mild liver disease, and CLDQ might overlook QOL...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Liver Disease and Transplantation
• Share to Liver Disease Diagnosis and Treatment
• Share to Liver Diseases and Immunity